Updated 2023 GOLD Report Revises COPD Definitions and …
2023年1月20日 · The 2023 report from the Global Initiative for Chronic Obstructive Lung Disease (GOLD) — “Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease” (COPD) 1 — details “an expanded range of therapies for COPD that now can be considered to improve mortality,” according to Gerard J. Criner, MD, FACP, FACCP, an author of the 2023 GOLD ...
GOLD COPD Report 2025: Key Spirometry and Drug Updates
2024年11月22日 · The 2025 GOLD COPD report includes a new emphasis on CV disease and PH in COPD and major updates on spirometry, new COPD drugs, climate change, and more. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) released its 2025 updated version of the GOLD Chronic Obstructive Pulmonary Disease (COPD) report earlier this month, just in ...
2024 GOLD Report Reflects New Research on COPD Management
2023年12月8日 · The 2024 GOLD Report, “Global Strategy for Prevention Diagnosis and Management of COPD,” not only includes guideline updates that reflect the latest research on chronic obstructive pulmonary disease (COPD); it also reflects some shifts in thinking about what’s important in COPD treatment, according to Claus Vogelmeier, MD, a lead report author and science committee chair for the Global ...
Tezepelumab Gets Breakthrough Therapy Status for COPD Tx
2024年8月12日 · The primary endpoint was COPD exacerbation rate. Findings showed in the overall population, treatment with tezepelumab led to a 17% reduction (90% CI, -6, 36; P =.1042) in the annual rate of moderate to severe COPD exacerbations compared with placebo (annualized rate of exacerbations: 1.75 with tezepelumab vs 2.11 with placebo).
GINA 2024 Asthma Update: Revised Recommendations on …
2024年6月28日 · Children: Initial Treatment Recommendations. Initial asthma treatment recommendations in children aged 6 to 11 years also have been updated. Symptom levels and lung function for initial treatment steps are similar to those for adults and adolescents. Additional details have been provided about studies, populations, and outcomes in this age group.
Optimism and Caution Lead the Way in Stem Cell Therapy …
2021年7月9日 · Researchers are currently exploring the use of stem cell therapies in a range of conditions including cardiovascular disease, neurodegenerative disorders, and chronic obstructive pulmonary disease (COPD), among others. 1,2 To date, however, these products have been approved by the U.S. Food and Drug Administration (FDA) only for use in certain cancers, hematological diseases, and immune system ...
2024 GOLD Guidelines Stress the Importance of Vaccines for …
2024年1月5日 · At least 70% of COPD exacerbations are infectious in origin, with respiratory viruses identified in approximately 30% of cases,” noted the study authors. 3. Vaccination Rates in Patients With COPD. Not enough individuals with COPD are properly vaccinated, stressed authors of the European Respiratory Review article.
Dupixent Approved as Add-On Maintenance Therapy in COPD
2024年10月1日 · Treatment with dupilumab reduced the annualized rate of moderate or severe COPD exacerbations by 30% in the BOREAS trial and 34% in the NOTUS trial compared with placebo. The Food and Drug Administration (FDA) has approved Dupixent (dupilumab) as an add-on maintenance therapy for adults with inadequately controlled chronic obstructive pulmonary ...
Breathing New Life Into COPD and Asthma Therapy With Statins
2018年4月23日 · A year later, Chinese researchers found in a meta-analysis of 15 studies comprising 238,459 patients that statins had a beneficial effect on COPD. 3 Statins reduced all-cause mortality by 38% (95% CI, 0.52-0.73) and COPD mortality by 52% (95% CI, 0.23-0.99). 3 Of the 15 studies, 6 showed that statins reduced the risk for COPD exacerbations by ...
Early Care by Pulmonologist Linked to Better Outcomes in Asthma …
2024年6月11日 · At 12 months, 232 participants (92%) in the intervention group and 153 (60%) in the usual care group initiated a new treatment for asthma or COPD. The intervention group had a lower annualized rate of participant-initiated health care use for respiratory illness vs the usual care group (0.53 vs 1.12 events per person-year; incidence rate ratio ...